

Clinical Advisory Group Recruitment Pack

Terms of Reference

Our Clinical Advisory Group is a multidisciplinary panel where members bring their clinical expertise and real-world experience to provide support and insight to teams across Prostate Cancer UK.

Role of the Clinical Advisory Group

- Work collaboratively to advise and support on specific issues relating to prostate cancer
- Inform the charity of real time challenges faced by men with prostate cancer and clinical staff delivering care in the NHS
- Ensure that the work of the charity remains focussed on reflecting the care and support needs of men living and dying well with prostate cancer
- Contribute to consultations on challenging and complex issues such as drug access, PSA/screening, diagnostic pathway, and pandemic recovery

What we expect from you

Membership

All CAG members will be expected to commit to a 3-year tenure with an option to renew for a further 3-year tenure, however additional experts may be recruited into the group at the discretion of the CAG and Prostate Cancer UK.

Nonattendance at two or more meetings within 12 months will result in review of membership.

Time Commitment

It is anticipated that members will meet on a quarterly basis for a maximum of 3 hours each quarter.

Outside of quarterly meeting members may be asked to attend ad hoc meetings to address urgent, unanticipated matters as they arise. Specific working groups may be formed where appropriate.

We will consult with members about the balance between face to face and virtual meetings, but anticipate that mostly meetings will be virtual, although aim to hold 1 face to face meeting each year.



A specific meeting agenda will be developed outlining areas of intended discussion, and papers will be shared at least 7 days in advance.

At least 6-8 weeks' notice of the meetings will be given. Where possible meeting dates will be set a year in advance.

Prostate Cancer UK will ensure that you are reimbursed for any travel and accommodation costs that you incur in relation to the CAG

How to apply

<u>Click here</u> to complete the online application form. Within your application, please outline your interest in this position and the skills and expertise that make you a suitable candidate for the Clinical Advisory Group.

Application Deadline


Closing date for this application is: 11.59pm 8 December 2022

Shortlisted candidates will then be interviewed via Microsoft Teams.

Further information

If you would like more information about the CAG, please contact **Kavita Tailor** at Improvement@prostatecanceruk.org

For more information, please refer to Prostate Cancer UK's 3-year strategy below.



Prostate Cancer UK Strategy 2022-2025

The Why and What?

The needs of men

- 1. To know what a prostate is/to know how to take control of the risk of prostate cancer
- 2. To be engaged in a way that aligns to my culture, beliefs, and rituals and gives me a voice
- 3. A reliable test/screening programme that diagnoses my cancer whilst it can still be cured
- 4. Open and transparent support to enable informed choices re: diagnosis and treatment and give back control
- 5. Better and more accurate treatments that give men the best chance of survival with the minimum necessary side effects
- 6. A robust, systematic active surveillance programme where my emotional wellbeing is also supported
- 7. To live with the disease so I can have the best quality of life possible and die well
- 8. To be empowered to use my experience to help others

Long term ambition

To save and improve the lives of men affected by prostate cancer

Every day purpose

We are all pulling together to ensure men live longer and better because we find diagnostic and treatment solutions, help men take back control and make informed choices about their prostate cancer. We influence government decision makers to improve men's outcomes and experiences. We offer hope that the next generation of men will not be affected so badly by prostate cancer.

Strategic pillars

Reach and activate more men to make an informed choice about their prostate cancer risk Reduce health inequalities and become relevant to the communities most impacted, starting with Black Accelerate early diagnosis and the delivery of better, more precise treatments Transform the experience and support for men with prostate cancer to live and die well

Business drivers

To ensure the brand is mission/impact led, attractive to desired segmented audiences and associated with synergistic brand partners

Grow our income from £34.6M to £40M over the next 3 years with a view to reaching £50M by 2027

To invest and develop our culture and people; ensuring we have an inspired, motivated, and skilled workforce working with efficient interoperability who are supported through any change management

To develop the insight and involvement of customers, particularly those affected by prostate cancer, underpinned by a data strategy to understand, and serve everybody who engages with us